Senescence marker p16INK4a expression in patients with multiple sclerosis

Area of Science:

• Immunology
• Neuroscience
• Aging Research

Background:

• Telomere attrition, linked to cellular senescence, is associated with disability and brain atrophy in multiple sclerosis (MS).
• Cellular senescence is a key downstream effect of telomere attrition, impacting tissue aging and disease progression.
• Understanding cellular senescence markers like p16INK4a is crucial for investigating aging processes in MS.

Purpose of the Study:

• To investigate differences in p16INK4a expression between MS patients and healthy controls.
• To determine the association between p16INK4a expression and MS-related disability.
• To explore the relationship between p16INK4a expression and exposure to MS treatments.

Main Methods:

• A cross-sectional pilot study involving MS patients and healthy controls.
• RNA extraction from peripheral blood mononuclear cells (PBMCs) for p16INK4a expression measurement via qRT-PCR.
• Statistical analysis using Spearman correlations and regression models to assess associations with age, clinical outcomes, and treatment exposure.

Main Results:

• No linear correlation was found between p16INK4a levels and chronological age in either MS patients or controls.
• Higher median p16INK4a levels were observed in participants over 50 years old with MS compared to controls.
• In the >50 age group, B cell depletion therapy was associated with lower p16INK4a expression; however, p16INK4a expression did not correlate with MS disability outcomes.

Conclusions:

• p16INK4a expression in PBMCs may not be a reliable biomarker for chronological aging in MS patients.
• The lack of strong correlation with age and clinical outcomes suggests caution in using this marker for aging assessment in MS.
• Further research is needed to identify robust biomarkers of aging and senescence in multiple sclerosis.